Description

CD150 is a 75-95 kD member of the immunoglobulin superfamily, also known as SLAM (signaling lymphocyte activation molecule) or IPO-3. CD150, a single chain type I transmembrane molecule, is expressed on thymocytes, T cell subsets, B cells, dendritic cells, and endothelial cells. The expression is upregulated upon activation. CD150 expression has been shown to be maintained on Th1 but not Th2 clones. T regulatory cells express a relatively high level of CD150. Antibodies against CD150 have been shown to augment IFN-γ production by Th1 cells, especially when co-stimulated through the TCR. CD150 associates with the src homology 2-domain-containing protein tyrosine phosphatase SHP-2, and this association is thought to be involved in signal transduction. In combination with CD48, CD150 is a useful marker for hematopoietic stem cell studies.

Formulation

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microL sizes, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.125 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Castro AG, et al. 1999. J. Immunol. 163:5860. (FC, Costim, IP)
2. Forsberg EC, et al. 2005. PLoS Genet. 1:e28. (FC)
3. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (FC)
4. Cannons JL, et al. 2006. J. Exp. Med. 203:1551. (FC)
5. Umemoto T, et al. 2006. J. Immunol. 177:7733. (FC)
6. Jordan MA, et al. 2007. J. Immunol. 178:1618. (FC, Block) PubMed
7. Jung Y, et al. 2007. Blood 110:82. PubMed
8. Pimanda JE, et al. 2007. Proc. Natl. Acad. Sci. USA 104:840.
9. Sugiyama T, et al. 2007. Proc. Natl. Acad. Sci. USA 104:175.
10. Kim I, et al. 2006. Blood 108:737. PubMed
11. Ema H, et al. 2006. Nat Protoc. 1:2979. PubMed
12. Fraser ST, et al. 2007. Blood 109:4616. PubMed
13. Jung Y, et al. 2008. Stem Cells. 26:2042. Pubmed
14. Song J, et al. 2010. Blood 115:2592. PubMed
15. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 43:149. (FC) PubMed
16. Morita Y, et al. 2010. J. Exp Med. 207:1173. PubMed